Stem cell transplant or rescue: patient has not had a prior stem cell transplant or rescue
No prior treatment with high-dose chemotherapy (defined as treatment utilizing stem cell rescue)
Patient must be >=  months since high dose chemotherapy and peripheral blood stem cell rescue prior to registration
Previous high-dose chemotherapy requiring stem cell rescue.
Must not be eligible for high-dose therapy with autologous stem cell transplantation rescue
Prior high dose chemotherapy requiring stem cell rescue.
Histologically confirmed non-Hodgkin lymphoma and be considered ineligible for standard curative therapeutic options, including high dose chemotherapy with autologous stem cell rescue
Previous high-dose chemotherapy requiring allogenic stem cell rescue.
History of bone marrow transplant and stem cell rescue
Patients who have received any of the following:\r\n* >  chemotherapy regimens\r\n* Myeloablative chemotherapy with stem cell rescue\r\n* Craniospinal irradiation
Previous high-dose chemotherapy requiring stem cell rescue
Bone marrow transplant or stem cell rescue
Eligible for high-dose therapy and autologous stem-cell rescue
Comorbid condition(s) which, in the opinion of the attending physician and/or MSK Cancer Center (CC) principal investigator, will preclude stem cell mobilization and/or high-dose therapy with autologous stem cell rescue
Meets standard eligibility requirements for high dose chemotherapy with autologous stem cell rescue (COHORT ) or allogeneic hematopoietic stem cell transplant (COHORT ) and has signed consent for those procedures
History of organ allograft (except for corneal transplant) or autologous or allogeneic bone marrow transplant, or stem cell rescue within  months prior to the first dose of IMP
Patients must have a minimum stem cell dose of x^ CD+ MNC/kg stored for autologous stem cell rescue
Autologous bone marrow transplant or stem cell rescue within four months of start of study drug
Treatment with high-dose chemotherapy and hematopoietic stem-cell rescue within  months prior to initiation of study drug
High-dose chemotherapy with stem-cell rescue: interval >=  months before study enrollment
Autologous stem cell rescue within  weeks before study enrollment or those who underwent allogeneic stem cell transplant within one year of enrollment
Patients with multiple myeloma who are potential candidates for high dose chemotherapy with stem cell rescue
Autologous bone marrow transplant or stem cell rescue within  months of study entry
Autologous bone marrow transplant or stem cell rescue within  months of study entry
Scheduled to receive stem cell rescue therapy in conjunction with study related course(s) of emetogenic chemotherapy
History of organ allograft (except for corneal transplant) or autologous or allogeneic bone marrow transplant, or stem cell rescue within  months prior to the first dose of study drug.
Frequent use of rescue opioids >  x/day or rescue bronchodilators >  x/day over last  hours
Approved rescue medication for the treatment of nausea and vomiting is permitted at the discretion of the investigator; the rescue antiemetics allowed will include: ondansetron, granisetron and lorazepam
ONCOLOGY PATIENTS: patients with an oncology diagnosis that are or will be on a chemotherapy regimen that will last for an additional >=  months or are on or will be on a chemotherapy regimen for <  months and then proceed to transplant (allogeneic or autologous stem cell rescue) during the -month study period
Allogenic bone marrow transplant or stem cell rescue within  months before first dose of study drug; patients must have completed immunosuppressive therapy before enrollment
Will be receiving stem cell rescue therapy in conjunction with study-related course of emetogenic chemotherapy or during the  days following administration of fosaprepitant/placebo for fosaprepitant
Patients with a history of organ transplant including high dose chemotherapy with autologous stem cell rescue